ClinicalTrials.gov
ClinicalTrials.gov Menu

Topiramate for Cryptogenic Sensory Peripheral Neuropathy in Metabolic Syndrome (CSPN) (TopCSPN)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02878798
Recruitment Status : Recruiting
First Posted : August 25, 2016
Last Update Posted : December 13, 2018
Sponsor:
Collaborators:
National Institute of Neurological Disorders and Stroke (NINDS)
NeuroNEXT Network
University of Utah
Information provided by (Responsible Party):
Virginia Commonwealth University

August 11, 2016
August 25, 2016
December 13, 2018
February 12, 2018
March 2019   (Final data collection date for primary outcome measure)
  • Intraepidermal nerve fiber density (IENFD) [ Time Frame: Baseline 9, 18, and 24 months ]
    Difference in IENFD change between treatment groups over 24 months.
  • Norfolk Quality of Life - Diabetic Neuropathy [ Time Frame: Baseline, 9, 18, and 24 months ]
    Difference in NQOL between treatment groups over 24 months.
Same as current
Complete list of historical versions of study NCT02878798 on ClinicalTrials.gov Archive Site
  • Nerve conduction studies [ Time Frame: Baseline, 9, 18, and 24 months ]
    association of NCS outcomes to NQOL and IENFD changes
  • Utah Early Neuropathy Scale [ Time Frame: Baseline, 4, 8, 12, 16, 20, 24 months ]
    association of UENS to NQOL and IENFD changes
  • Timed up and Go [ Time Frame: Baseline, 9, 18 and 24 months ]
    association of TUG change to NQOL and IENFD changes
  • 6 Minute Walk Test [ Time Frame: Baseline, 9, 18, and 24 months ]
    association of 6MW change to NQOL and IENFD changes
  • Neuropathy Total Symptom Score - 6 [ Time Frame: Baseline, 4, 8, 12, 16, 20, 24 months ]
  • Brief pain inventory [ Time Frame: Baseline, 4, 8, 12, 16, 20, 24 months ]
    association of BPI change to NQOL and IENFD changes
  • Nerve conduction studies [ Time Frame: Baseline, 9, 18, and 24 months ]
    association of NCS outcomes to NQOL and IENFD changes
  • Utah Early Neuropathy Scale [ Time Frame: Baseline, 4, 8, 12, 16, 20, 24 months ]
    association of UENS to NQOL and IENFD changes
  • Timed up and Go [ Time Frame: Baseline, 9, 18 and 24 months ]
    association of TUG change to NQOL and IENFD changes
  • 6 Minute Walk Test [ Time Frame: Baseline, 9, 18, and 24 months ]
    association of 6MW change to NQOL and IENFD changes
  • Neuropathy Total Symptom Score - 6 [ Time Frame: Baseline, 4, 8, 12, 16, 20, 24 months ]
  • Berg Balance Test [ Time Frame: Baseline, 9, 18, and 24 months ]
    association of BBT change to NQOL and IENFD changes
  • Visual analog pain scale [ Time Frame: Baseline, 4, 8, 12, 16, 20, 24 months ]
    association of VAS change to NQOL and IENFD changes
  • Brief pain inventory [ Time Frame: Baseline, 4, 8, 12, 16, 20, 24 months ]
    association of BPI change to NQOL and IENFD changes
  • Mini-Best Test [ Time Frame: Baseline, 4, 8, 12, 16, 20, 24 months ]
    association of MBT change to NQOL and IENFD changes
Not Provided
Not Provided
 
Topiramate for Cryptogenic Sensory Peripheral Neuropathy in Metabolic Syndrome (CSPN)
Topiramate as a Disease Modifying Therapy for Cryptogenic Sensory Peripheral Neuropathy in Metabolic Syndrome (CSPN)
The TopCSPN trial is a double blinded randomized placebo controlled study of oral topiramate as a potential disease altering therapy for cryptogenic sensory peripheral neuropathy (CSPN). Patients with CSPN who also have metabolic syndrome (defined by the ATPIII criteria) who do not have an alternative cause for neuropathy will be potentially eligible. The co primary outcome measures are change in the Norfolk Quality of Life - Diabetic Neuropathy (NQOL-DN) Scale and intraepidermal nerve fiber density (IEFND) at the distal thigh. The treatment phase will last 24 months.
Not Provided
Interventional
Phase 2
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Cryptogenic Sensory Peripheral Neuropathy in Metabolic Syndrome
  • Drug: topiramate
    Oral topiramate at a target dose of 50mg twice daily.
    Other Name: Topamax
  • Other: Placebo
    overencapsulated placebo of identical color, shape and packaging to topiramate
  • Placebo Comparator: Placebo
    An overencapsulated placebo of identical color, shape and packaging to topiramate will be used.
    Intervention: Other: Placebo
  • Experimental: Topiramate
    Oral topiramate
    Intervention: Drug: topiramate
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
125
Same as current
December 2021
March 2019   (Final data collection date for primary outcome measure)

Inclusion Criteria

  1. Age 18-80
  2. Diagnosis of confirmed cryptogenic symptomatic distal symmetric peripheral polyneuropathy based on the Toronto consensus criteria for probable neuropathy (the presence of unequivocal signs and symptoms of neuropathy)
  3. Evidence of symptomatic neuropathy based on a screening visit NQOL-DN score of >9
  4. Metabolic syndrome based on modified ATPIII criteria, with a BMI ≥ 25 kg/m2. Specific criteria require 3 of the following 6 to be present at the screening visit.

    • Waist circumference >102 cm for men, >88 cm for women
    • Serum triglycerides of > 150 mg/dl
    • HDL < 40 mg/dl for men, < 50 mg/dl for women
    • Those with either a normal HDL or TRG who are taking a lipid lowering medication for this purpose.
    • Blood pressure 130/85 mm Hg or use of anti-hypertension drug
    • Prediabetes based on American Diabetes Association (ADA) criteria at screening based on any one or more of the following: fasting plasma glucose - 100 mg/dL to 125 mg/dL (5.6 mmol/L to 6.9 mmol/L), 2-hour glucose tolerance test - 140 mg/dL to 199 mg/dL (7.8 mmol/L to 11.0 mmol/L), or hemoglobin A1c between 5.7% and 6.4%.
  5. No current or prior history of therapy with topiramate.
  6. If female of child-bearing potential (i.e., not surgically sterile or post-menopausal defined as age > 51 years without menses for ≥ 2 years), negative serum pregnancy test at screening and negative urine pregnancy test at baseline visit.
  7. Women of child-bearing potential or men with sexual partners of childbearing potential be willing to use an acceptable method of birth control for the duration of the study and for 12 weeks following completion of study drug therapy. Acceptable methods of birth control include abstinence, oral contraceptives, the contraceptive patch, intra-uterine device, the contraceptive ring, and or barrier contraception such as condoms with spermicide.

Exclusion Criteria

  1. CSS-PI clinical determination of an alternative cause for peripheral neuropathy (including but not limited to rheumatological disorders, Hepatitis B or C, Breast Cancer treated with neurotoxic chemotherapy within the past 15 years). All potential subjects will have screening neuropathy labs including assessment for diabetes (Hemoglobin A1c, oral glucose tolerance test), vitamin B12 level, and immunofixation.
  2. Diagnosis of diabetes by history, or screening laboratory results including: HgA1c ≥ 6.5%, fasting plasma glucose ≥ 126 mg/dL (7.0 mmol/L), or 2-hour oral glucose tolerance ≥ 200 mg/dL (11.1 mmol/L). Borderline screening labs can be repeated within two weeks with PPI approval.
  3. History of recurrent nephrolithiasis, a single episode of nephrolithiasis within one year prior to screening, or use of ongoing preventative treatment.
  4. Family history of a hereditary neuropathy in a first-degree relative.
  5. Severe neuropathy: Utah Early Neuropathy Score > 24 at screening
  6. Active foot ulceration or a history of a nontraumatic foot amputation.
  7. ECG with QTc more than 450 ms in men, or 470 ms in women.
  8. Current or planned therapeutic anticoagulation including coumadin or oral factor X or thrombin inhibitor therapy (anti-platelet agents are permissible).
  9. Chronic corticosteroid use excluding topical or inhaled treatment.
  10. Use of a carbonic anhydrase inhibitor (such as acetazolamide) due to risk of nephrolithiasis.
  11. Planned bariatric surgery
  12. Use of other weight loss medications.
  13. Use of scheduled opiates, or as needed opiate medications more than three times weekly.
  14. Use of topical capsaicin products within 16 weeks of screening or at any time on study.
  15. Medication change for neuropathy symptoms during the 8 weeks prior to screening; or anticipated change for the duration of study participation.
  16. Current use of an intrathecal pain pump or spinal cord stimulator.
  17. Screening laboratory creatinine ≥ 2.0 mg/dl.
  18. Severe edema, dermatologic or lower extremity condition that would increase risk of skin biopsy.
  19. Major depression, bipolar affective disorder, or other mental health disorders that are sufficiently severe to increase adverse event risk or impact neuropathy assessment in the opinion of the responsible site principal investigator.
  20. Current suicidal ideation within one year prior to the baseline visit as evidenced by answering "yes" to Questions 4 or 5 on the suicidal ideation portion of the Columbia-Suicide Severity Rating Scale (C-SSRS).
  21. Ataxia sufficiently severe to represent an unacceptable fall risk in the opinion of the site principal investigator.
  22. A serious medical condition expected to dramatically shorten life span or prevent participation.
  23. Any clinically significant condition or illness, which, in the opinion of the CSS-PI, would pose a risk to the subject or might confound the study including metabolic acidosis, bone marrow suppression, blood dyscrasias, bleeding disorder, or closed angle glaucoma.
  24. History of alcohol or drug abuse within the past two years, or existing neuropathy related to past drug or alcohol abuse.
  25. History of malignancy within five years prior to study enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer.
  26. A history of epilepsy.
  27. An inability to understand or cooperate with the procedures of the study
  28. Pregnant, or intending to become pregnant, or breastfeeding.
Sexes Eligible for Study: All
18 Years to 80 Years   (Adult, Older Adult)
No
Contact: Gordon Smith, MD 804-828-9556 gordon.smith@vcuhealth.org
Contact: Brittney A Holmberg 804-628-6439 brittney.holmberg@vcuhealth.org
United States
 
 
NCT02878798
URNN001 / HM20014083
1U01NS095388 ( U.S. NIH Grant/Contract )
Yes
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Not Provided
Virginia Commonwealth University
Virginia Commonwealth University
  • National Institute of Neurological Disorders and Stroke (NINDS)
  • NeuroNEXT Network
  • University of Utah
Principal Investigator: Gordon Smith, MD Virginia Commonwealth University
Virginia Commonwealth University
December 2018

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP